a Department of Internal Medicine , Taichung Veterans General Hospital, Chiayi branch , Chiayi , Taiwan.
b Division of Endocrinology and Metabolism, Department of Internal Medicine , Taichung Veterans General Hospital , Taichung , Taiwan.
Curr Med Res Opin. 2018 Nov;34(11):1885-1892. doi: 10.1080/03007995.2018.1439829. Epub 2018 Mar 12.
To investigate the effects of statins on all-cause mortality risk at different low-density lipoprotein cholesterol (LDL-C) levels, and to compare the mortality risk between statin users and non-users with identical LDL-C levels in a type 2 diabetes cohort.
In total, 10,582 outpatients aged ≥18 years with type 2 diabetes mellitus (T2DM) between 2009 and 2012 were enrolled in this retrospective cohort study in central Taiwan. All-cause mortality events were followed up until the end of 2014. According to the medical records during the follow-up period, the patients were classified into statin (+) and statin (-) groups. Patients were categorized into different LDL-C segments based on their mean LDL-C levels during the 2.8-year follow-up.
Non-cardiovascular mortality accounted for more than half the deaths. Overall, statin therapy significantly reduced the all-cause mortality risk in both univariable and multivariable models (hazard ratios = 0.39 and 0.38, respectively). Sub-group analyses showed that the lowest mortality risk occurred in the 80-89 mg/dL segment in the statin (-) group and in the 90-99 mg/dL segment in the statin (+) group. Statin therapy significantly reduced the mortality risk at all LDL-C levels except for low LDL-C (<60 mg/dL).
In addition to reducing LDL-C levels, statin therapy reduced all-cause mortality risk in Taiwanese patients with T2DM. Statins further reduced the mortality risk at most LDL levels. However, at low LDL-C levels, the positive effects of statins may have been nullified.
探讨他汀类药物在不同低密度脂蛋白胆固醇(LDL-C)水平下对全因死亡率风险的影响,并在 2 型糖尿病队列中比较 LDL-C 水平相同的他汀类药物使用者和非使用者的死亡率风险。
本回顾性队列研究共纳入 2009 年至 2012 年间年龄≥18 岁的 10582 例在台中部就诊的 2 型糖尿病(T2DM)门诊患者。所有患者均随访至 2014 年底。根据随访期间的病历记录,患者被分为他汀类药物(+)和他汀类药物(-)组。根据 2.8 年随访期间的平均 LDL-C 水平,患者被分为不同的 LDL-C 段。
非心血管死亡率占死亡人数的一半以上。总体而言,他汀类药物治疗在单变量和多变量模型中均显著降低了全因死亡率风险(风险比分别为 0.39 和 0.38)。亚组分析显示,他汀类药物(-)组 LDL-C 水平在 80-89mg/dL 段和他汀类药物(+)组 LDL-C 水平在 90-99mg/dL 段的死亡率风险最低。他汀类药物治疗除了降低 LDL-C 水平外,还显著降低了 T2DM 患者的全因死亡率风险,除了 LDL-C 水平较低(<60mg/dL)外,他汀类药物治疗在大多数 LDL-C 水平上进一步降低了死亡率风险。
除了降低 LDL-C 水平外,他汀类药物治疗还降低了台湾 T2DM 患者的全因死亡率风险。他汀类药物进一步降低了大多数 LDL 水平的死亡率风险。然而,在 LDL-C 水平较低时,他汀类药物的积极作用可能已经失效。